Hypokalemia is a recognized adverse effect of thiazide diuretic treatment. This phenomenon, which may impair insulin secretion, has been suggested to be a reason for the adverse effects on glucose metabolism associated with thiazide diuretic treatment of hypertension. However, the mechanisms underlying thiazide diuretic-induced hypokalemia are not well understood. In an effort to identify genes or genomic regions associated with potassium response to hydrochlorothiazide, without a priori knowledge of biologic effects, we performed a genome-wide association study and a multiethnic meta-analysis in 718 European-and African-American hypertensive participants from two different pharmacogenetic studies. Single-nucleotide polymorphisms rs10845697 (Bayes factor = 5.560) on chromosome 12, near to the HEME binding protein 1 gene, and rs11135740 (Bayes factor = 5.258) on chromosome 8, near to the Mitoferrin-1 gene, reached genome-wide association study significance (Bayes factor 45). These results, if replicated, suggest a novel mechanism involving effects of genes in the HEME pathway influencing hydrochlorothiazideinduced renal potassium loss.
JL Del-Aguila 1 , RM Cooper-DeHoff 2 , AB Chapman 3 , JG Gums 2 , AL Beitelshees 4 , K Bailey 5 , ST Turner 5 , JA Johnson 2 and E Boerwinkle 1, 6 Hypokalemia is a recognized adverse effect of thiazide diuretic treatment. This phenomenon, which may impair insulin secretion, has been suggested to be a reason for the adverse effects on glucose metabolism associated with thiazide diuretic treatment of hypertension. However, the mechanisms underlying thiazide diuretic-induced hypokalemia are not well understood. In an effort to identify genes or genomic regions associated with potassium response to hydrochlorothiazide, without a priori knowledge of biologic effects, we performed a genome-wide association study and a multiethnic meta-analysis in 718 European-and African-American hypertensive participants from two different pharmacogenetic studies. Single-nucleotide polymorphisms rs10845697 (Bayes factor = 5.560) on chromosome 12, near to the HEME binding protein 1 gene, and rs11135740 (Bayes factor = 5.258) on chromosome 8, near to the Mitoferrin-1 gene, reached genome-wide association study significance (Bayes factor 45). These results, if replicated, suggest a novel mechanism involving effects of genes in the HEME pathway influencing hydrochlorothiazideinduced renal potassium loss. Hypokalemia is a well-known consequence of thiazide diuretic treatment of patients with hypertension. 1, 2 Hypokalemic-impaired insulin secretion has been suggested to be a mechanism for the adverse metabolic effects accompanying diuretic treatment, 3, 4 although this hypothesis is not universally supported. 5, 6 The mechanism by which diuretics lead to potassium wasting and hypokalemia in some patients but not others is not well understood. In an effort to identify genes or pathways associated with hydrochlorothiazide (HCTZ)-induced hypokalemia, we performed a genome-wide association study (GWAS) and a multiethnic meta-analysis (Meta-Analysis of Transethnic Association studies (MANTRA)) 7 in European-and African-American hypertensive patients from two different pharmacogenetic studies. The data presented here are the first GWAS to our knowledge of diuretic-induced potassium loss, and the analysis was conducted in four different study samples (European and African Americans each from two different studies). The results implicate the HEME pathway in affecting diuretic treatment-induced hypokalemia.
MATERIALS AND METHODS

Study population
Details of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study and the Genetic Epidemiology of Responses to Antihypertensive (GERA) study have been previously published. 8, 9 PEAR and GERA study participants were African Americans and European Americans with mild to moderate essential hypertension without a history of heart disease or diabetes mellitus. In PEAR, after a washout period of approximately 4 weeks, blood and urine were collected in a fasting state. After the baseline evaluations were completed, participants were randomized to HCTZ (thiazide diuretic 12.5 mg orally once daily) or atenolol (β-blocker 50 mg orally once daily) for 3 weeks, with dose doubling (to 25 mg HCTZ) for those with BP 4120/70 mm Hg for an additional 6 weeks. More than 90% of PEAR participants received the higher 25 mg dose of HCTZ. For this analysis of potassium (K+) response, we used only those randomized to the HCTZ arm, referred to hereafter as PEAR HCTZ monotherapy.
In GERA, after a washout period of at least 4 weeks, blood samples were obtained for baseline biochemical measurement, and then qualifying participants were treated with HCTZ (25 mg orally once daily) for 4 weeks. At the end of the 4-week diuretic treatment period, blood pressure was measured and blood samples were again obtained for biochemical measurements. All blood collections were carried out in the morning after 8 hrs of fasting.
All participants enrolled in PEAR and GERA provided written informed consent, and the institutional review boards of participating study centers approved the study protocols.
Phenotype and genotype data
Serum potassium concentrations, in PEAR and GERA studies, were measured by flame photometer (Instrumentation Laboratories model 943, Lexington, MA, USA). Plasma insulin, which was used as a covariate during statistical analyses, was measured in both studies with the Access Ultrasensitive Insulin immunoassay system (Beckman Coulter, Brea, CA, USA).
In GERA, serum potassium concentration was determined after 2 weeks of HCTZ therapy. In PEAR, serum potassium concentrations were measured at the end of the washout period (baseline), after 3 weeks and at the end of the HCTZ monotherapy. In both studies, there were protocol-mandated potassium supplementation requirements based on serum potassium levels. Potassium supplementation was required for values o3.6 mEq l − 1 in GERA and o3.2 mEq l − 1 in PEAR. Potassium supplementation was also available for use by the study physician, at their discretion, at higher potassium levels. To avoid confounding from prescribed potassium supplementation and to promote patient safety, serum potassium response to HCTZ was defined as the difference between the levels measured after the first visit (2 weeks in GERA and 3 weeks in PEAR) of treatment and the baseline visit, before initiation of potassium supplementation. Thirteen participants with potassium response values under or over 3 s.d. from the mean response were removed from the analysis.
Participants were genotyped using the Illumina HumanOmni1-Quad (Illumina, San Diego, CA, USA) in the case of PEAR and the GeneChip Human Mapping 500k Array (Affymetrics, Santa Clara, CA, USA) in the case of GERA. Standard quality control steps were applied to the raw genotype data in both studies: single-nucleotide polymorphisms (SNPs) with minor allele frequency o1%, call rates o95%, Hardy-Weinberg equilibrium P-values ⩾ 10 − 5 and participants with more than 10% missing genotypes were removed from the analysis. The software MACH 10 (http: www.sph. umich.edu/csg/abecasis/MACH/download) was used to impute the approximate 2.5 million HapMap SNPs using the Phase II CEU as the reference panel for European Americans and a cosmopolitan sample of CEU and YRI for African Americans. Quality control filters for the imputed results were RSQ_HAT o0.3 and minor allele frequency ⩽ 0.05. MACH generated a file with the highest posterior probabilities for each imputed SNP (i.e. dosage), which was used in the analysis. After quality control and imputation, there were more than two million SNPs used for the genotype-phenotype association studies in each race-study group.
Statistical analysis
Additive genetic association analyses of potassium response to HCTZ were performed by self-reported race within each study using ProbABEL, 11 while adjusting for sex, age, waist circumference, the baseline values of potassium and insulin and the two first principal component scores, to avoid the possibility of spurious association as the result of population substructure. 12, 13 The principal components were calculated using the EIGENSTRAT 12 software. The European-American and African-American GWAS analyses were combined via transethnic meta-analysis using MANTRA. 7 MANTRA clusters populations by the mean allele frequency difference. If populations are in the same cluster, MANTRA assumes that they have the same underlying allelic effects and a fixed-effect model is performed. On the other hand, if populations are in different clusters, the assumption will be that they do not have the same underlying allelic effect and a random-effect analysis is performed. MANTRA provides a combined association signal called a Bayes factor (BF) instead of a traditional P-value to compare the null and alternative hypotheses. BF compares how well two hypotheses agree with the observed data. In the present case, we compare the agreement of the data under a null model of no association of the variant with the trait in any population, with the alternative model that there is an association in at least one population. The hypothesis that agrees with the observed data better is the one that is said to have more evidence supporting it. A BF of 10 5 , roughly corresponding to a P-value of 7.9 × 10 − 7 , was considered a significant evidence of association 14 after accounting for genome-wide multiple comparisons. 15 
RESULTS
Tables 1A and B summarize the baseline characteristics of the European-American and African-American study participants, respectively. Both studies had a higher percentage of European-American male and African-American female study participants. The average age and waist circumference was nearly identical between PEAR and GERA. Baseline potassium was lower in African Americans from GERA compared with the other groups. The mean response in European Americans was lower compared with African Americans. Figure 1 shows the distribution of potassium response in both populations after removing 13 outlier individuals.
No genome-wide significant association was found in each separate study and race group (Supplementary Information). After the multiethnic meta-analysis, the top seven SNPs from MANTRA are shown in Table 2 , and four of them, located in three different loci, reached genome-wide significant significance evidence of association. A Manhattan plot of the BFs is shown in Figure 2 (BF = 5.258) on chromosome 8, near to the Mitoferrin-1 (SLC25A37 also known as MFRN1) gene. The effects of rs10845697 were not consistent among study samples ( Table 2 ). Whether this inconsistency is because of chance sampling variation, differences in linkage disequilibrium or differences in allelic effects among the study samples is not known. Because HEBP1 and SLC25A37 are related to HEME synthesis, we carried out a targeted analysis of other genes and SNPs related to HEME synthesis. Although rs12095896 on chromosome 1 did not reach GWAS significance (BF = 4.980), it was found in the region of the genome previously related to bilirubin levels (http://www. genome.gov/gwastudies/index.cfm?pageid = 26525384#searchForm). Bilirubin is a bile pigment that is a degradation product of HEME. Rs10845697 near HEBP1, rs11135740 near SLC25A37 and rs12095896 in the bilirubin locus combined accounted for 5% and 7% of the variance of potassium response in PEAR and GERA European Americans, respectively. In African Americans, these values were 16% for PEAR and 12% for GERA. The effect size estimates of the top signals from the HEME synthesis pathway are shown in Table 3 .
DISCUSSION
Hypokalemia is a well-known adverse effect in patients taking HCTZ. The purpose of this study was to identify genes or genomic regions associated with potassium response after HCTZ treatment. We conducted a GWAS and a multiethnic meta-analysis (i.e. MANTRA) from two studies of hypertensive European-and African-American individuals. Four SNPs achieved a log 10 BF45, which was defined a priori to be GWAS significance evidence of association. Confirmation of these results will be required in an independent sample of hypertensive patients treated with HCTZ. Among the top SNPs, rs10845697 near HEBP1 and rs11135740 near Mitoferrin-1 (SLC25A37) have a role in heme biosynthesis. [16] [17] [18] [19] Heme has been identified as a modulator of the large-conductance Ca 2+ -activated K + channels (BK, or maxi K). 20 BK channels are located in the medullary, cortical thick ascending limbs [21] [22] [23] and the distal convoluted tubule 24 in the kidney. They are sensitive to change in both voltage and calcium concentration and they work as volume regulatory channels and secrete potassium. 25 However, they have not previously been considered important contributors to renal potassium secretion because of their low open probabilities (P o ) as well as their low concentration on the principal cell in the collecting ducts of the kidney. 25 The main route for potassium secretion is considered to be the inwardly rectifying channel, subfamily J, member 1 encoded by the gene KCNJ1, which has higher P o and higher density on principal cells than BK channels. 26 Although KCNJ1 has shown significant associations with change in glucose in multiple studies, 27, 28 SNPs in and around KCNJ1 were not associated with potassium response to HCTZ (data not shown) in this study.
We hypothesize that HCTZ affects serum K in part by influencing heme levels; the bulk of the effect would be inhibition of Na-Cl cotransporter. Heme has been shown to increase the P o of the BK channels at negative voltages and decrease it at more positive voltages. 29 As a result, the secretion of potassium by BK channels would be positively associated with heme levels.
Herein, we report the first GWAS to our knowledge of potassium response to HCTZ and provide evidence for a novel mechanism of HCTZ-induced hypokalemia. Our study is unique in that it included a washout of all antihypertensive agents before initiation of HCTZ and collected detailed data regarding potassium supplementation and levels. However, there are weaknesses that must be acknowledged; for instance, although MANTRA can provide an overall BF as the combined association signal, it fails to estimate a proper combined effect size from the joint analysis of all the studies. Another weakness is the absence of replication sample. During this study, we contacted multiple potential collaborators in the United States and Europe, but none had appropriate potassium response data to serve as a replication for this study. This experience underscores the need for an international pharmacogenetics of antihypertinsive consortium. Abbreviations: GERA, Genetic Epidemiology of Responses to Antihypertensive; GWAS, genome-wide association study; PEAR, Pharmacogenomic Evaluation of Antihypertensive Responses.
